ADC Therapeutics

ADC Therapeutics is a commercial-stage biotechnology company that develops targeted antibody drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. The company's lead product, ZYNLONTA, is an FDA-approved anti-CD19 ADC used to treat adults with relapsed or refractory large B-cell lymphoma after two or more prior lines of therapy. Their research pipeline focuses on expanding ZYNLONTA into earlier lines of treatment and developing new therapies for patients with recurring cancers that do not respond to standard treatments.